Supernus Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Supernus Pharmaceuticals

06/08/2024 23:01

* Supernus Pharmaceuticals Inc  SUPN.OQ  reported quarterly
adjusted earnings of 36 cents​​ per share for the quarter ended
in June, higher than the same quarter last year, when the
company reported EPS of -2 cents.  The mean expectation of
four analysts for the quarter was for earnings of 39 cents per
share. Wall Street expected results to range from 32 cents to 44
cents per share.
    * Revenue rose 24.2% to $168.33 million from a year ago;
analysts
expected $148.85 million. 
    * Supernus Pharmaceuticals Inc shares had risen by 4.4% this
quarter and lost 3.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 5.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Supernus
Pharmaceuticals Inc is $40.50 
This summary was machine generated from LSEG data August 6 at
10:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      0.39           0.36           Missed
 Mar. 31 2024      0.38           0.26           Missed
 Dec. 31 2023      0.55           0.89           Beat
 Sep. 30 2023                     0.24